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1. Introduction 
The majority of systemic amyloid disorders are acquired in nature and are most often 
secondary to plasma cell dyscrasias (AL amyloid), age-related accumulation of transthyretin 
(senile ATTR amyloid) or chronic inflammation (AA amyloid). A smaller, though 
significant, fraction of cases are due to inherited mutations in one of several amyloidogenic 
proteins. As described elsewhere in this volume, amyloid consists of fibrils composed of 
stacked proteins which have adopted a beta pleated sheet conformation. The mechanism by 
which a protein which has substantial alpha helical character refolds into a configuration 
with it’s primarily beta pleated sheet is unclear and is the subject of much ongoing research. 
It is clear, however, that specific amino acid substitutions in a small number of circulating 
proteins can accelerate or facilitate this process. 
All of the hereditary amyloidoses (also known as familial or systemic amyloidoses) are 
inherited in an autosomal dominant manner, as is the case for other “gain of function” 
mutations in disorders such as Huntington disease, myotonic dystrophy, or the 
spinocerebellar ataxias. The dominant inheritance of the familial amyloidoses has 
implications for family members of an affected individual. First, careful attention to the 
family history will often reveal symptoms in one parent, which may or may not have come 
to medical attention. However, even in the setting of a thorough family history, hereditary 
amyloidosis can be missed and attributed to more common diseases. It is important to 
understand that siblings and children of an affected individual have a 1 in 2 chance of being 
affected themselves. Thus, after the identification of an amyloidogenic mutation in an 
individual, it is important to offer testing for at-risk family members so that appropriate 
monitoring can be carried out for mutation positive family members. 
The hereditary amyloidoses involve deposition of amyloid in a variety of tissues. Typically, 
there is a proclivity for the vascular tree, particularly the microvasculature, and it can be a 
cause of cerebral hemorrhage. The kidneys and the heart are the most commonly involved 
organs. However, virtually any organ can become involved, with liver, spleen, thyroid, larynx, 
gastric wall, and salivary glands all described. Further, amyloid deposition can also occur in 
the soft tissue adjacent to the salivary gland, tracheobronchial tree, the tongue, and in the skin.. 
On physical examination this diverse distribution manifests with a similar broad spectrum 
of features including macroglossia, peripheral edema, peripheral neuropathy, hypertension, 
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papular rash, and waxy papules. Patients may demonstrate congestive heart failure as part 
of the restrictive cardiomyopathy conferred due to the amyloid deposition within cardiac 
muscle. Additionally, gastric dysmotility occurs, and cerebral hemorrhage is documented, 
as previously mentioned. 
Clinically, it may be difficult to distinguish amyloidosis that is secondary to overproduction 
of immunoglobulin light chains (AL amyloid), age-related ATTR amyloidosis or serum 
amyloid A (AA amyloid) from an amyloidosis that is hereditary in nature. As the treatment 
for the underlying cause of amyloidosis is drastically different for the different etiologies, it 
is critical that the amyloid be properly classified. Therapy for plasma cell disease can 
include chemotherapy and/or bone marrow transplant, and the therapy for AA amyloid 
involves addressing the underling cause of inflammation, while the curative treatment for 
two varieties of familial amyloidosis, including the most common form due to mutant 
transthyretin (ATTR amyloid) is liver transplant. 
To make a diagnosis, including identification of the protein being deposited as amyloid 
fibrils, it is typically necessary to obtain biopsy material from an affected organ or site. Most 
often, biopsies are obtained from either the bone marrow, subcutaneous fat (often of the 
abdomen), or the rectum. Following tissue acquisition, a variety of methods are used in 
identifying and characterizing amyloid protein. These include Congo Red staining, 
immunoperoxidase staining of histological tissue, mass spectrometry and genetic evaluation 
in cases of familial disease. 
While the majority of systemic amyloidosis is due to transthyretin (TTR) mutations, 
identification of other genes involved in conferring aberrant protein folding with 
subsequent amyloid deposition have been identified. These additional genes have been 
documented in a substantially smaller number of individuals than TTR mutations and 
include ApoA1, ApoA2, gelsolin, lysozyme, and fibrinogen alpha (FGA). By and large, 
the most common symptom of these genetic variants is nephropathy. However, the 
gelsolin variant of disease does not involve the kidneys, rather it displays a 
predisposition for cranial nerve tissue, lattice corneal dystrophy, and cutis laxa of the 
facial skin. As gelsolin amyloidosis was originally identified in a large Finnish family , 
and is more common, but not limited to individuals of Finnish descent, it is often 
referred to as Finnish amyloidosis. 
The differential diagnosis of systemic amyloidosis includes light chain disease, Sjögren’s 
syndrome, rheumatoid arthritis, other inflammatory conditions, β2-microglobulinemia, and 
Familial Mediterranean Fever, as well as other similar conditions. A discussion of a 
thorough diagnostic evaluation for these conditions is beyond the scope of this chapter. 
However, a few key laboratory tests can expedite the process: serum protein electrophoresis 
(assists in the diagnosis of light chain disease or β2-microglobulinemia), the presence of 
antinuclear antibody and SSBLa>SSBRo by immunofluoresence for Sjögren’s syndrome. The 
presence of rheumatoid factor points towards Rheumatoid Arthritis. Detection of serum 
amyloid A in amyloid deposits by immunohistochemistry elicits a definitive diagnosis of 
AA amyloid, or amyloid deposition of an inflammatory origin. 
With respect to AL amyloidosis, while serum protein electrophoresis is the classical 
method of working up this diagnosis, ruling out hereditary amyloidosis through DNA 
interrogation is pivotal. Studies have demonstrated that individuals with hereditary 
amyloidosis may also demonstrate monoclonal immunoglobulins on serum protein 
electrophoresis in as many as 24% of patients. In the study by Lachmann et al., all of the 
patients had less than 0.2 g/dL of immunoglobulins in the serum, and none of the 
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patients had kappa or lambda free light chains by urine protein electrophoresis. Comenzo 
et al. had similar findings, with six percent of patients with a hereditary amyloidosis 
presenting definitive monoclonal gammopathies in a subject population of similar size. 
The differences between these two studies is that the patients with monoclonal 
gammopathy in the Lachmann et al. study demonstrated mutations in a variety of genes 
for hereditary amyloidosis, whereas in the Comenzo et al. study, all patients had TTR 
mutations. In the absence of DNA analysis, these patients with hereditary amyloidosis 
masquerading with a monoclonal gammopathy would be misdiagnosed, and the 
improper clinical management could be implemented. 
2. Methods used for the evaluation of tissue amyloid 
2.1 Congo red staining 
The gold standard for the detection of the presence of amyloid is Congo Red staining 
(Figure 1). A paper by Cooper  compared Congo Red staining against other techniques to 
detect amyloid at the time, and his findings demonstrated that the green birefringence 
demonstrated under polarized light was completely specific for the presence of amyloid. A 
positive Congo Red stain on a biopsy or fat aspirate does not give the specific precursor 
protein causing the amyloid deposition. It does, however, define the presence of amyloid, 
setting the stage for further diagnostic evaluation.  
 
 
 
 
 
 
 
Fig. 1. Cardiac biopsy from a patient with TTR amyloidosis by hematoxylin and eosin 
(left), Congo Red (middle), Congo Red under polarized light with apple green 
birefringence (right). (Courtesy of Ahmet Dogan, MD, PhD; Mayo Clinic, Rochester, 
MN). 
2.2 Immunohistochemistry 
Immunohistochemistry (IHC) has been in use for many years to identify the specific 
protein involved in amyloid deposits identified by Congo red staining. In principle, IHC 
can differentiate the most common types of amyloid, light chain, serum amyloid A, and 
transthyretin (Figure 2). However, it is the authors’ experience that, with the exception of 
serum amyloid A, the results can be equivocal and difficult to interpret. One of the 
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problems is that the epitopes that specific antisera recognize can be partially or even 
completely buried in the insoluble amyloid fibril. There is a lack of high affinity 
antibodies specific for amyloidogenic proteins in the beta pleated sheet conformation. 
Further, a trained eye for interpretation of the results is required, with the ability to 
discern a poor staining pattern (such as that seen with serum leakage into amyloid 
plaques), and to recognize nonspecific or non-contributory background staining (low 
specificity and sensitivity). In addition, the adverse effects of changing protein structure 
by crosslinking due to formalin fixation limits the utility of immunohistochemistry in 
detecting amyloid deposition (demonstration of this phenomena thus far has been limited 
to TTR). If TTR is identified, IHC is unable to distinguish between a mutant TTR protein 
in a case of familial amyloid and a wild-type protein in case of senile amyloid (see the 
discussion of TTR and ApoA2 amyloid below). Finally, typical IHC panels consisting of 
antibodies to kappa and lambda light chains, serum amyloid A, and TTR, cannot identify 
the presence of less common amyloids consisting of lysozyme, gelsolin, fibrinogen alpha, 
or apolipoproteins 1, or 2. 
 
 
 
 
 
 
 
Fig. 2. Cardiac biopsy with TTR amyloid, positive for TTR by immunohistochemistry 
(photograph courtesy of Ahmet Dogan, MD, PhD; Mayo Clinic, Rochester, MN). 
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2.3 Electron microscopy 
Ultrastructural examination (electron microscopy) of amyloid is not a common method of 
identifying this pathology. However, on ultrastructural examination, amyloid has a fibrillar 
pattern  (Figure 3). Of note, there are several other fibrillary diseases of the kidney such as 
fibrillary glomerulonephritis and immunotactoid glomerulopathy, both of which are 
completely different entities than hereditary amyloid. Thus, fibrillary glomerular deposits 
by electron microscopy are non-specific, and additional studies are warranted to determine 
their etiology. 
 
 
Fig. 3. Electron microscopy of amyloid fibrils measuring 6-10 nanometers in a patient with 
cardiac amyloidosis (photograph courtesy of Ahmet Dogan, MD, PhD; Mayo Clinic, 
Rochester, MN). 
2.4 Mass spectrometry 
More recently with new technological developments, mass spectrometry (MS) based 
proteomic methodologies have been applied to subtype amyloidosis. Initial studies using 
MS, similar to amino acid sequencing approaches, required large quantities of fresh or 
frozen tissue with a heavy amyloid load. However, in recent years, the sensitivity of MS 
based technologies has significantly improved and methods to extract proteins and peptides 
from small amounts of clinical biopsy specimens have been developed. This has led to 
development of a highly sensitive and specific clinical test for typing of amyloid deposits in 
paraffin embedded tissues. The approach incorporates laser capture microdissection (LCM) 
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of amyloid plaques up front which dramatically increases the amount of proportion signal 
coming from the amyloidogenic protein compared to the signal coming from the 
background tissue (Figure 4). 
 
 
Fig. 4. AA amyloidosis showing predominantly vascular deposition with Congo red 
staining. For mass spectrometry based proteomic analysis, the areas circled by yellow lines 
are microdissected with laser and the microdissected fragments are collected in the tube cap 
ready for protein extraction and digestion into peptides suitable for tandem mass 
spectrometry (courtesy of Ahmet Dogan, MD, PhD; Mayo Clinic, Rochester, MN). 
Once the amyloid plaques are captured, they are fragmented by heating and sonication to 
reverse crosslinking caused by formalin fixation, followed by digestion into peptide fragments 
by trypsin. Trypsin specifically cleaves the proteins following lysine and arginine residues and 
generates a peptide “soup.” For each protein a specific and reproducible set of peptides is 
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generated. The peptide solution is fractionated by high performance liquid chromatography 
and peptides are introduced into the mass spectrometer by a process called electrospray 
ionization (ESI). ESI provides the interface between the liquid environment of the HPLC and 
the high vacuum environment of the MS. It also adds charges to the peptides so that they can 
be detected and manipulated by MS. After ESI, the peptides are analyzed by tandem MS/MS. 
The first MS detects mass/charge ratio (m/z) of each peptide (precursor ion) as they are 
focused in the mass spectrometer. Based on relative abundance and other preset criteria, a 
subset of the charged peptides are selected for collision-induced dissociation. This leads to 
fragmentation of the peptides into smaller charged particles (product ions). Mass/charge ratio 
of these fragments is captured by the second MS (tandem mass spectrometry, MS/MS). This 
raw MS data is then interrogated by bio-informatic algorithms which match the fragmentation 
pattern of each peptide to one of the theoretical tryptic peptides present in human proteome. 
In this way, amino acid sequence of each peptide analyzed by MS/MS is predicted with high 
specificity. Proteins are identified and displayed in order of relative abundance based on the 
total number of peptide spectra identified for each protein (Figure 5). Using this approach 
amyloid deposits can be subtyped by very high sensitivity and specificity (100% for both in the 
published validation set) (Vrana et al., 2009). 
 
 
Fig. 5. Mass spectrometry based proteomic analysis of hereditary amyloidosis. Transthyretin 
(red arrow) is the most dominant amyloidogenic protein in all four microdissections 
studied. Gene sequencing confirmed Val50Met in this case. (courtesy of Ahmet Dogan, MD, 
PhD; Mayo Clinic, Rochester, MN). 
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3. Genetic evaluation of familial amyloidosis 
3.1 Genetic evaluation 
Gene sequencing is the gold standard to detect aberrations such as substitutions, and 
small deletions and insertions at the nucleotide level. Sequencing is particularly useful 
when heterogeneity occurs in a disease, as with amyloidosis. The familial amyloidoses 
display both genetic heterogeneity (multiple genes being involved in a disease) and 
allelic heterogeneity (multiple mutations in the sample gene being able to cause the 
disease). 
The first step in any DNA sequencing is the extraction, or purification, of DNA, typically 
from a peripheral blood sample. Many platforms are available for DNA extraction, the 
authors use the MagNaPure® LC (Roche Diagnostics). Following DNA extraction, the 
samples are prepared for PCR with primers specific to the gene of interest, and the standard 
PCR constituents (Taq polymerase, buffer, magnesium chloride and PCR-grade water). The 
authors perform a gel electrophoresis next to confirm the PCR reaction prior to proceeding 
with the sequencing assay. Next, the PCR product is treated, or “cleaned” to remove 
unincorporated primers and nucleotides. Again, there are multiple ways that this can be 
accomplished. The authors utilize shrimp alkaline phosphatase (to convert unincorporated 
deoxynucleotide triphosphates (dNTP’s) into dephosphorylated products that will not 
interfere with the downstream sequencing reaction) and exonuclease (to digest unextended 
PCR primers into nucleotides to prevent unwanted extension during the sequencing 
reaction). The cleaned PCR product is next combined with a mixture of fluorescently labeled 
di-deoxynucleotide triphosphates and dNTP’s (ex: BigDye® terminators [Applied 
Biosystems]), sequencing buffer, PCR grade water, and a thermostabile DNA polymerase. 
After carrying out the sequencing reaction by thermal cycling and another purification step, 
this time removing unincorporated fluorescent material, the sample is analyzed by capillary 
electrophoresis. There are multiple software programs commercially available for base 
calling, alignments, and mutation detection. The authors use Mutation Surveyor® (Soft 
Genetics) (Figure 6). 
4. Genes involved in hereditary amyloidosis 
4.1 Notes on nomenclature 
The Human Genome Variation Society (HGVS) has proposed standard nomenclature for 
variation both at the nucleotide and the protein level (www.hgvs.org/mutnomen/). In this 
chapter, all mutations and variants will be discussed referring to protein sequence, or amino 
acid changes. The HGVS recommends that proteins be numbered starting with the initiator 
methionine as amino acid number one. Older literature often uses a different convention. 
Previously, the standard nomenclature was to number the first amino acid of the mature, 
processed protein as amino acid number one. For secreted proteins (such as those involved 
in familial amyloidoses), this numbering system neglected the signal peptides and 
propeptides that are cleaved from the amino terminus after translation as the protein is 
being processed by the cell for secretion. All of the amino acid changes discussed here will 
use the HGVS standard nomenclature. 
For example, the signal peptide of the TTR protein is 20 amino acids in length. One mutation 
seen in TTR amyloid is Cys30Arg (new nomenclature). Using historical nomenclature, the 
mutation is termed Cys10Arg (subtract 20 amino acids that account for the signal peptide in  
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Fig. 6. Gene sequencing for lysozyme showing c. 388T>A, p. W130R, a pathogenic mutation. 
The top and bottom sequences (1 and 4) are the reference sequences against which the 
sample is compared. Sequences 2 and 3 are the patient sample. The top trace (1, 2) are 
sequenced in the forward direction, and the bottom trace (3, 4) in the reverse. The two 
middle traces are the subtraction plots between the reference sequence and the patient 
sample. The intronic region is indicated by the tan line, the yellow line indicates the exon. 
The pink peak is the location of the mutation (arrows), indicating substitution of a cytosine 
for a thymine. This nucleotide substitution alters the tryptophan (W) codon TGG to CGG, 
which codes for arginine (R). 
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the new nomenclature to derive this). Apolipoprotein A1 (ApoA1) is an example of a 
protein with a signal peptide and a propeptide. The signal peptide is 18 amino acids in 
length, and the propeptide is 6. Hence, to extrapolate the historical nomenclature from the 
new nomenclature for a mutation in ApoA1, Gly50Arg would be Gly26Arg. Please refer to 
Table 1 for a listing of all genes and the conversions. 
 
Protein Signal Peptide/Propeptide 
Example 
(historicalnew) 
TTR 20 Cys10ArgCys30Arg 
ApoA1 18/6 Gly26ArgGly50Arg 
ApoA2 18/5 Stop78SStop101S 
Gelsolin A 27 Asp187TyrAsp214Tyr 
Fibrinogen Alpha 19 Arg554LeuArg573Leu 
Lysozyme 18 W112RW130R 
Table 1. Table depicting nomenclature conversion from historical to new. The primary 
difference is that the new nomenclature includes all codons beginning with the initiating 
methionine, and the historical nomenclature utilizes only the mature protein. Hence, to 
convert to the new nomenclature requires adding the appropriate number of codons acting 
as signal peptides and propeptides, as indicated. 
4.2 Transthyretin (TTR) 
Transthyretin (TTR) was the first protein identified in hereditary amyloidosis with amyloid 
deposition due to coding sequence missense mutations was transthyretin. Notably, it is by 
far the most common protein and gene involved in familial amyloidosis, accounting for 
between 95-98% of reported familial amyloid cases, and often presenting after the age of 50. 
TTR is a transport protein that has four exons, 127 amino acids and weighs 55kDa, and is 
synthesized predominantly in the liver. The function of TTR is to carry thyroxine (T4) and to 
participate in the thyroxine-retinol binding protein complex. Consequently, when TTR is 
mutated, aberrant protein folding results with deposition as described above with the 
clinical sequelae including most predominantly peripheral polyneuropathy, and/or 
cardiomyopathy (with or without eye and brain involvement). 
Due to its predominantly hepatic synthesis, liver transplantation is the treatment of choice 
for patients with TTR amyloidosis. Since this treatment is vastly different than the cytotoxic 
chemotherapeutic regimens and/or bone marrow transplant indicated for AL amyloidosis, 
the correct diagnosis of these two disorders with supporting laboratory data is paramount. 
Also, senile amyloid deposition is often composed of wild-type TTR protein. In this case, the 
conversion of TTR into amyloid fibrils is not driven by pathogenic mutations. Gene 
sequencing is necessary to distinguish TTR type senile amyloid from a hereditary disorder. 
Though more than 100 mutations have been reported in TTR, almost all of them are due to 
single base substitutions in the gene, located on chromosome 18. Common single base 
substitutions include V50M, L75P, L78H, T80A, and Y134H. A common three-
nucleotide/single codon deletion is ∆Val142. Moreover, ethnic propensities exist such as the 
association of V142I with African Americans. Further, M33I is seen in the German 
population, A45T, Y89I, and Q112K segregate amongst the Japanese. Variants common in 
the United States are D38N, A45S, F53C, W61L, T69P, L75Q, A101T, and R123S.  Phenotypic 
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clustering is seen in some codon changes (Table 2), and Tyr89Ile is the only double 
nucleotide substitution documented to date. Specifically, Tyr89Ile is seen in the Japanese 
population, with cardiac and connective tissue involvement, and autonomic neuropathy. 
 
Mutation Clinical Features Geographic kindreds 
Phe53Ile Peripheral Neuropathy, Eye Israel 
Phe53Leu Peripheral Neuropathy, Heart USA 
Phe53Val Peripheral Neuropathy UK, Japan, China 
Ala65Thr Heart USA 
Ala65Asp Heart, Peripheral Neuropathy USA 
Ala65Ser Heart Sweden 
Ile104Asn Heart, Eye USA 
Ile104Thr Heart, Peripheral Neuropathy Germany, UK 
Glu109Gln Peripheral Neuropathy, Heart Italy 
Glu109Lys Peripheral Neuropathy, Heart USA 
Val142Ile Heart USA 
∆Val142 Heart, Peripheral Neuropathy USA 
Val142Ala Heart, Eye, Peripheral Neuropathy USA 
Table 2. Phenotypic correlations of TTR mutations along with segregation among particular 
geographic kindreds (adapted from Benson 2003 ). 
4.3 Apolipoprotein A1 (ApoA1) 
Apolipoprotein A1 (ApoA1), another protein involved with hereditary amyloidosis, 
contains four exons, 243 amino acids, weighs 28kDa, and is located on chromosome 11q23-
q24. ApoA1 is synthesized in the liver and small intestine, conferring a plasma protein that 
is the main protein of high-density lipoprotein particles and has a key role in lipoprotein 
metabolism. As such, ApoA1 is important for the formation of high-density lipoprotein 
cholesterol esters, promoting efflux of cholesterol from cells. Mutations in ApoA1 can lead 
to one of two rare disease of lipoprotein metabolism, primary hypoalphalipoproteinemia or 
Tangier’s disease; or, ApoA1 amyloidosis, depending on the mutation. Thirteen mutations 
are associated with ApoA1 amyloidosis, predominantly nucleotide substitutions. However, 
two are deletions, and one is a deletion/insertion mutation. Most of the deletionss are in-
frame, with the exception of Asn122fs and eAla202fs. Hence, the mechanism of amyloid 
production for all of the ApoA1 mutations involve aberrant folding, the unstable species 
produced with the Asn122fs and Ala202fs mutations is a truncated protein rather than a full 
length one. 
The clinical presentation of amyloidosis consistent with ApoA1 involves the liver, kidney, 
larynx, skin and myocardium most commonly; rarely the testes and adrenal glands. The 
most common mutations to date include G50R, L99P, A197P, A199P, and L198S. Most of 
these mutations are present in Northern Europeans. Specifically, G50R is common among 
British, Scandinavians and North Americans, L99P in Italians, Germans, and North 
Americans, A197P in Americans and British, and L198S in Italian and Dutch individuals  
(Table 3). 
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Mutation Clinical Features 
Gly50Arg Peripheral neuropathy, Nephropathy 
Glu58Lys Nephropathy 
Leu84Arg Nephropathy 
Glu94_Trp96del HTN, Nephropathy 
Trp74Arg Nephropathy 
Del84-85insVal/Thr Hepatic 
Leu88Pro Nephropathy 
Del94-96 Nephropathy 
Phe95Tyr Palate 
Asn98fs Nephropathy, gastrointestinal 
Leu99Pro Hepatic 
Leu114Pro Cardiomyopathy, cutaneous 
Lys131del Aortic intima 
Ala178fs Nephropathy 
Leu194Pro Laryngeal 
Arg197Pro Cardiomyopathy, cutaneous, laryngeal 
Leu198Ser Cardiomyopathy 
Ala199Pro Laryngeal 
Leu202His Cardiomyopathy, laryngeal 
Table 3. Common ApoA1 mutations (adapted from Benson, 2003; Eriksson, et al., 2009; 
Rowczenio, et al., In Progress).  
4.4 Apolipoprotein A2 (ApoA2) 
Apolipoprotein A2 (ApoA2), similar to ApoA1, is an amyloidogenic protein involved with 
lipid metabolism. ApoA2, unlike ApoA1, can be found in senile amyloidosis. As is the case 
with TTR, gene sequencing is required to determine if ApoA2 deposition in a given case is 
due to deposition of a wild-type protein (senile amyloid) or a mutant one (familial 
amyloidosis). Structurally, it is a 77 amino acid, 17.4kDa protein located on chromosome 
1p21-1qter. While comprised of four exons, three exons in ApoA2 are coding: exons 2, 3 and 
the 5’ end of exon 4 (Alamut). The Apo A2 gene is one of the more recently described forms 
of hereditary amyloid, with a clinical picture of early adult-onset, rapidly progressive renal 
failure. The abrupt renal failure occurs in the absence of proteinuria and has no associated 
neuropathy. Mutations in the stop codon are the common genetic change resulting in a 21-
amino acid extension at the carboxy terminus of the mature protein. All of these changes 
occur at codon 101 in exon 4 as follows: Stop101G, Stop101S, and Stop101R (Table 4). 
Geographically, these mutations are seen in North Americans, with the exception of 
Stop101R, which is also seen in Russians. 
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Protein Mutation Clinical Features 
ApoA2 Stop78Gly Nephropathy 
 Stop78Ser Nephropathy 
 Stop78Arg Nephropathy 
Gelsolin A Asp214Asn PN, LCD 
 Asp214Tyr PN 
Fibrinogen Alpha Arg573Leu Nephropathy 
 Glu545Val Nephropathy 
 1629delG Nephropathy 
 1622delT Nephropathy 
Lysozyme Ile74Thr Nephropathy, petechiae 
 Asp85His Nephropathy 
 Trp82Arg Nephropathy 
 Phe75Ile Nephropathy 
Table 4. Listing of common mutation for other amyloidogenic proteins. PN = Peripheral 
Neuropathy, LCD = lattice corneal dystrophy. 
4.5 Gelsolin A (GSN) 
Gelsolin protein is associated with actin metabolism. Also known as brevin, or, actin-
depolymerizing factor, it acts to prevent toxicity due to the release of actin into the 
extracellular space in the presence of cell necrosis. The gene is comprised of 17 exons and is 
located on chromosome 9q34 (centromeric to ABL); the protein weighs 82kDa. In the setting 
of familial/hereditary amyloidosis presents with unique features of neuropathy, 
particularly of the cranial nerves. Additionally, Gelsolin A has distinguishing clinical 
features that merit clinical, not genetic, subclassification of the disease. For example, some 
patients may have lattice corneal dystrophy, the “Meretoja” subtype, and cutis laxia of facial 
skin. Known pathogenic mutations include D214N in individuals from Finland, North 
America, Denmark and Japan, and D214Y (c. 654G>C), in individuals from Finland, 
Denmark, and the Czech Republic. The D214N and D214Y mutations permit exposure of an 
otherwise masked cleavage site, and is the initial step of amyloid formation. Both of these 
mutations result in the production of an aberrant, 68-kD fragment, likely a carboxy-terminal 
part of the protein which is suggested to be amyloidogenic. 
The Meretoja subtype is associated with the D214N mutation, a single base mutation c. 
654G>A (GAC>GAA), p. D214N (Asp214Asn). The pathogenic protein is comprised of 71 
amino acids. Individuals that are heterozygous for this mutation may be asymptomatic 
early in life, with possibly only lattice corneal dystrophy (in their thirties); those who are 
homozygous may have significant manifestations of visceral involvement, specifically renal, 
including proteinuria and amyloid nephropathy with nephrotic syndrome by their twenties. 
Regardless of the genotype, the gelsolin variant of amyloid is classically associated with 
cranial neuropathy, possibly even bilateral, with additional phenotypic features rendering 
subclassification as described herein  (Table 4). 
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4.6 Fibrinogen alpha (FGA) 
Synthesized in the liver, fibrinogen is a plasma glycoprotein with three structural subunits: 
alpha (FGA), beta (FGB), and gamma (FGG). Most research regarding fibrinogen has been in 
the context of hemostasis, where it has a primary functional role. Two rare diseases due to 
mutations in fibrinogen alpha confer bleeding disorders: afibrinogenemia and 
dysfibrinogenemia. Afibrinogenemia has an absence of fibrinogen due to a truncating 
mutation, and dysfibrinogenemia has decreased fibrin production due to a mutation at the 
cleavage site for thrombin to convert inactive fibrinogen to fibrin. The mutations seen with 
bleeding are different than those seen in FGA amyloid. Fibrinogen alpha is located on 
chromosome 4q28, with 6 exons, and varying amino acid lengths as determined by 
alternative splicing. 
Phenotypically, FGA amyloidosis is associated with visceral involvement, specifically renal, 
with the manifestations including hypertension, proteinuria, and subsequent azotemia. 
Importantly, renal involvement in amyloid of this genetic origin is associated with rapidly 
progressive renal failure. Hence, detection of amyloid with a FGA mutation, like TTR, 
permits consideration of liver transplant for curative treatment, and, perhaps, could avoid 
the negative consequences of renal disease. Historically, renal transplantation, which has 
also been performed, has not had long-term success, thus, this paradigm-shift to hepatic 
transplantation, especially in light of the ability to detect the mutation, is a promising 
alternative for patients. Neuropathy has not been seen in this type of amyloidosis, and 
cardiomyopathy is reported in one case, thus far. Hence, neurologic and cardiac 
involvement would be the exception rather than the rule at this early phase of diagnosing 
FGA amyloid. 
To date, there are four common mutations associated with FGA amyloidosis: two point 
mutations with pathogenic single amino acid substitutions, and two single nucleotide 
deletions yielding a frameshift in DNA transcription, with subsequent premature 
termination of protein synthesis. One point mutation, c. 4993 G>T, p. R573L has been 
identified in a Peruvian family, and another, c. 1674 A>T, p. E545V has been detected in 
individuals of American and Irish descent. Specifically, the E545V mutation is the one 
example of cardiac manifestations of FGA amyloid. One mutation, 1629delG, a deletion of 
the third base in codon 543, was detected in an American family with hereditary renal 
amyloidosis. Due to this mutation, a premature stop codon is created at codon 567. 
Individuals with the 1629delG mutation had a later onset of disease (later thirties and early 
forties) when compared to those with the R573L mutation . Finally, early renal disease with 
terminal renal failure has been documented in French kindred with a single nucleotide 
deletion c.1622T, with subsequent frameshift mutation at codon 541 and, similar to 
1629delG, premature termination of protein synthesis at codon 567  (Table 4). This particular 
subtype, with its inherently aggressive sequelae, is particularly relevant to consideration of 
liver transplantation early in the course of disease. 
4.7 Lysozyme (LYZ) 
Lysozyme is an enzyme that catalyzes the hydrolysis of certain mucopolysaccharides of 
bacterial cell walls. Specifically, it catalyzes the hydrolysis of the beta (1-4) glycosidic linkages 
between N-acetylmuramic acid and N-acetylglucosamine. Lysozyme is found in the spleen, 
lung, kidney, white blood cells, plasma, saliva, milk and tears. The gene is located on 
chromosome 12q15 and contains 4 exons. The 14.6kDa protein contains 130 amino acids. 
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In the same vein with regard to management, early detection of this amyloid variant alters 
the course of treatment in that individuals with this mutation experience a very early 
onset of renal disease, with rapid decline (this is similar, in some regards, to some variants 
of FGA). However, unlike FGA, benefit from renal transplantation has proven effective. 
Other manifestations include gastrointestinal involvement (peptic ulcer), cardiac disease, 
Sicca syndrome, and propensity towards petechiae, hemorrhage and hematoma, 
including hepatic hemorrhage. Uniquely, neuropathy is not a component of this type of 
amyloid, and in fact, might suggest a different variant, such as gelsolin, depending on the 
presentation. 
The mutations documented thus far with lysozyme amyloid have their ancestral roots 
associated with the United Kingdom, France, America, and Italy (specifically, Piedmont, 
Italy). The D85H (Asp85His) mutation regionalizes to the United Kingdom, renal disease 
is the predominant symptom associated with this mutation. A tryptophan-to-arginine 
substitution at codon 82 (W82R) has been documented with a French family, with Sicca 
syndrome contributing to the phenotype in addition to renal manifestations. Two other 
mutations, Phe75Ile (F75I), and Trp82Arg (W82R), are described in an Italian-Canadian 
family, and an Italian family (Piedmont, Italy), respectively. The W82R variant had 
predominant gastrointestinal involvement; however, the same mutation in an  
English man presented with dramatic bleeding and rupture of abdominal lymph nodes  
(Table 4). 
4.8 LECT2: A new hereditary amyloidosis gene? 
The most recently described gene in systemic amyloidosis is LECT2. LECT2 is a leukocyte 
chemotactic factor whose synthetic origin is uncertain at this time (Benson 2010). Some 
studies indicate a hepatic origin as LECT2 is expressed in the adult and fetal liver, but 
follow-up immunohistochemical studies have detected LECT2 in many tissues of the body. 
LECT2 weighs 16.4kDa, is comprised of 133 residues (after cleavage of the 18 amino acid 
signal peptide), and is located on chromosome 5q31.1-q32. 
Functionally, LECT2 can serve as a cartilage growth factor (chondromodulin II), as well as in 
neutrophil chemotaxis, as the name implies. With its role in neutrophilic chemotaxis, LECT2 
has a presumable role in cell growth and repair after damage. Further, LECT2 has also been 
detected in hepatocellular carcinoma cell lines, suggesting a role in neoplasia, and also 
supporting its potential origin within hepatic tissue. 
To date, LECT2 amyloidosis has been seen primarily in individuals of Mexican American 
ancestry. A study by Murphy et al.  reported a series of 21,985 consecutive renal biopsies, of 
which 285 had positive Congo Red staining. Seven of ten cases with LECT2 renal 
amyloidosis were of Mexican descent. In some cases (typically reported in smaller studies), 
the amyloid was detected after longstanding, slowly progressive renal disease. 
The case reported by Benson  is a patient with a long history or slowly progressive renal 
failure, without a diagnosis of amyloidosis including its specific subtype until nephrectomy 
due to renal-cell carcinoma. Moreover, since its recent discovery, there is suggestion by 
Larsen et al.  that the incidence of LECT2 amyloid might actually exceed TTR. While a 
polymorphism has been detected in all of the cases affected with LECT2 amyloid (Ile58Val), 
no pathogenic mutations are present to date. Thus, whether or not LECT2 will emerge under 
the category of systemic or hereditary amyloidosis is yet to be determined.  
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5. Conclusion 
In summary, many laboratory techniques to detect and characterize the presence of amyloid 
are available. With these tools, the ability to detect the presence of amyloid has improved, as 
well as our ability to better understand the varying presentations and pathologic processes 
associated with the presence of amyloid. 
While the understanding of amyloid continues to evolve, so does our ability to detect, 
diagnose, and treat the varying etiologies. Two techniques pivotal this progress are tissue 
mass spectrometry and gene sequencing. The refined finesse available utilizing mass 
spectrometry and gene sequencing continues to unravel the amyloid puzzle, and reveal 
more patients, with more unique phenotypic expression of disease. As our ability to identify 
and characterize systemic amyloidosis improves, and genotype-phenotype correlations 
become more clear, it will likely be possible in the future to explain seemingly unique 
manifestations of the disease, such as the cardiac specific presentation seen with the V142I 
TTR mutation. 
The ultimate beneficiary of the utility of the refined laboratory diagnosis of amyloidosis is, 
of course, the patient. However, the information gathered due to test results is best handled 
in a multidisciplinary practice with well-established genetic counseling to educate the 
patient and family regarding the disease process, screening, and treatment considerations. 
At present, no direct pharmacologic therapy “cures” for the amyloid disease. However, 
understanding the origin of the proteins involved in the subtypes has achieved better 
control of this process in some types (TTR, FGA). 
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